MERZ-THERAPEUTICS
31.8.2021 13:06:13 CEST | Business Wire | Press release
Today, Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, has been granted the use of XEOMIN® for the symptomatic treatment in children and adolescents aged 2 to 17 years and weighing ≥ 12 kg of chronic sialorrhea due to neurological / neurodevelopmental disorders on EU level.1 The national approvals of the country authorities involved will follow in the next weeks. The U.S. Food and Drug Administration granted approval in December 2020, and the Russian Federal Service for Surveillance in Healthcare in spring 2021.
Stefan Brinkmann, CEO Merz Therapeutics: “At Merz Therapeutics, we do everything to bring better outcomes to more patients. As XEOMIN® is already approved for the treatment of adult sialorrhea, we can now offer life-long treatment with our botulinum toxin A, staying a trusted partner for sialorrhea patients as well as their relatives and physicians for a lifetime.”
Dr. Marcus Gollub, President, Head of Region Europe complements: “Pediatric sialorrhea is a serious condition that can significantly impact not only the medical condition but also the quality of life of the children and their families. I am happy that with this new indication we are able to take care of the needs of those children suffering from drooling and contribute to a better life for them and their families.”
Sialorrhea, also known as drooling, is a symptom that occurs when excessive saliva accumulates in the mouth. It is a chronic impairment often seen in children with neurological disorders (e.g. cerebral palsy or traumatic brain injury) and/or intellectual disability or neurodegenerative diseases.
The approval by European authorities for the use of XEOMIN® for pediatric patients suffering from chronic sialorrhea, was achieved due to the convincing results of the SIPEXI study (Si alorrhea Pe diatric X eomin I nvestigation). It was a prospective, randomized, double-blind, placebo-controlled, multicenter phase III study with an extension phase evaluating the safety and efficacy of XEOMIN® in 255 children and adolescents aged 2 – 17 years up to 64 weeks. The study recently got published in Neurology, the premier peer-reviewed journal for clinical neurology research.2
XEOMIN® is being distributed by Merz Pharmaceuticals GmbH in more than 70 countries to treat patients with upper and lower limb spasticity, cervical dystonia, blepharospasm or hypersalivation. Merz uses state-of-the-art technology in its dedicated facility in Dessau, Germany, meeting the highest international standards for biologic manufacturing. The highly purified 150kDa neurotoxin is the only active ingredient in XEOMIN® . It is produced by removing complexing proteins from botulinum toxin type A, using XTRACT® purification technology developed by Merz Pharma GmbH & Co. KGaA.
XEOMIN® is the registered trademark of Merz Pharma GmbH & Co. KGaA.
1
European SmPC (Summary of product characteristics), 2021-08-31
2
Berweck et al. Neurology. 2021 Aug 2:10.1212/WNL.0000000000012573. doi: 10.1212/WNL.0000000000012573.
About Merz Therapeutics
Merz Therapeutics, a business of Merz Pharmaceuticals GmbH, is dedicated to improving the lives of patients around the world. With its relentless research, development, and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurological conditions, liver disease, and other health conditions that severely impact patients’ quality of life. Merz Therapeutics is headquartered in Frankfurt, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Pharmaceuticals GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated more than 110 years to developing innovations that meet patient and customer needs.
Please visit www.merz.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210831005540/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines to Announce First Quarter 2026 Financial Results on May 622.4.2026 12:01:00 CEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its first quarter 2026 financial results on Wednesday, May 6, 2026 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com.To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capa
Smartstream Research Reveals Five Realities Redefining Buy-Side Reconciliations22.4.2026 10:05:00 CEST | Press release
Key Facts Over 70% of firms still rely primarily on end-of-day reconciliation, while 53% cite timing differences and data mismatches as the leading causes of breaks. 59% of participants identified external data dependencies as the primary risk, while 47% highlighted internal inconsistencies. And 41% struggle with incomplete or insufficiently enriched data. 69% describe their T+1 model as partially adapted and still evolving. Whilst 41% say T+1 has made data quality a critical priority. Smartstream, the trusted data solutions provider for leading global financial institutions and enterprises, today announces new findings from its latest industry research report, Smart Reconciliations: The Buy-Side Perspective, highlighting the structural shifts transforming reconciliation, control, and operational confidence across buy-side firms. Based on insights gathered from a roundtable of senior operations leaders across asset management and investment firms, the report identifies five critical re
‘Concrete in Life 2025/26’ Winners Announced – Spectacular Photographs From Around the World22.4.2026 10:00:00 CEST | Press release
Concrete in Life Photo of the Year from the Philippines wins $10,000 top prize Over 20,000 international entries from professional photographers and smartphone amateurs Concrete is the world’s most used substance after water Powerful and striking images from around the world have been chosen as the winners of the Concrete in Life 2025/26 global photography competition, showcasing the essential role concrete plays in daily life, infrastructure, cities, and design. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422352135/en/ OVERALL WINNER: Pillars Across the Sea by Celbert Palaganas, Cebu City, Philippines Run by the Global Cement and Concrete Association (GCCA), the annual competition received more than 20,000 entries from professional and amateur photographers, as well as smartphone users, spanning every continent. The competition highlights how concrete supports modern life while also offering moments of beauty, creativ
Netceed Publishes Its First Environmental, Social and Governance Report22.4.2026 09:30:00 CEST | Press release
Netceed, a global infrastructure supply chain solutions provider, has published our first Annual Environmental, Social and Governance (ESG) Report, marking a major milestone in the Group’s sustainability journey and reinforcing our commitment to transparency, accountability, and responsible business practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422579806/en/ Netceed Sustainability Report 2025 The report presents Netceed’s progress across environmental, social, and governance topics, including the verification of its carbon footprint data by an independent third party and the completion of its first climate risk analysis. Key highlights include: A reduction in Scope 1 and 2 CO2e emissions compared to 2024 Improved gender diversity in senior management positions – we now have 23% of senior management positions filled by women 70% of our suppliers (by spend) are working with us on our climate action priorities A
IONCHI byder AITO velkommen til at gå sammen med BMW og Mercedes-Benz om at udvikle premium høj-effekt opladningsnetværk i Kina22.4.2026 09:21:00 CEST | Pressemeddelelse
IONCHI, et joint venture mellem BMW og Mercedes-Benz inden for høj-effekt opladningstjenester, annoncerede i dag, at SERES vil tiltræde selskabet som en ligeværdig aktionær. Gennem denne kapitalinvestering vil AITO, premium-brandet fra SERES Group, støtte udviklingen af IONCHIs premium opladningsinfrastruktur. Med denne udvidelse fortsætter IONCHI med at levere premium opladningstjenester gennem avanceret teknologi og digitale services til alle kvalificerede køretøjer, samtidig med at der tilbydes eksklusive opladningsoplevelser til kunder hos BMW, AITO og Mercedes-Benz. Det udvidede trepartssamarbejde markerer begyndelsen på et nyt kapitel for premium opladningsnetværket og muliggør yderligere vækst samt en bredere kundedækning. Hver af de tre aktionærer vil eje en andel på 33,3 % i joint venturet. Etableret i 2024 har IONCHI til formål at løfte Kinas premium-oplevelse inden for elektrisk mobilitet gennem et avanceret offentligt høj-effekt opladningsnetværk. Netværket prioriterer attr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom